

Ming-Lun Yeh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8966180/publications.pdf>

Version: 2024-02-01

156
papers

2,319
citations

257450

24
h-index

315739

38
g-index

158
all docs

158
docs citations

158
times ranked

2538
citing authors

#	ARTICLE	IF	CITATIONS
1	Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. <i>The Lancet Gastroenterology and Hepatology</i> , 2018, 3, 172-180.	8.1	132
2	Baseline gamma-glutamyl transferase levels strongly correlate with hepatocellular carcinoma development in non-cirrhotic patients with successful hepatitis C virus eradication. <i>Journal of Hepatology</i> , 2014, 61, 67-74.	3.7	110
3	Huge Gap Between Clinical Efficacy and Community Effectiveness in the Treatment of Chronic Hepatitis C. <i>Medicine (United States)</i> , 2015, 94, e690.	1.0	94
4	Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 271-280.	0.4	72
5	Hepatitis B-related outcomes following direct-acting antiviral therapy in Taiwanese patients with chronic HBV/HCV co-infection. <i>Journal of Hepatology</i> , 2020, 73, 62-71.	3.7	60
6	Reactivation of hepatitis B in patients of chronic hepatitis C with hepatitis B virus infection treated with direct acting antivirals. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 1754-1762.	2.8	59
7	High hepatitis B virus surface antigen levels and favorable interleukin 28B genotype predict spontaneous hepatitis C virus clearance in uremic patients. <i>Journal of Hepatology</i> , 2014, 60, 253-259.	3.7	58
8	Real-World Effectiveness From the Asia Pacific Rim Liver Consortium for HBV Risk Score for the Prediction of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Treated With Oral Antiviral Therapy. <i>Journal of Infectious Diseases</i> , 2020, 221, 389-399.	4.0	58
9	Association Between Fatty Liver and Cirrhosis, Hepatocellular Carcinoma, and Hepatitis B Surface Antigen Seroclearance in Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 294-302.	4.0	51
10	Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1. <i>Antiviral Research</i> , 2012, 93, 239-244.	4.1	44
11	Hepatitis C Virus Infection among Injection Drug Users with and without Human Immunodeficiency Virus Co-Infection. <i>PLoS ONE</i> , 2014, 9, e94791.	2.5	44
12	Impact of tumor size on the prognosis of hepatocellular carcinoma in patients who underwent liver resection. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 155-163.	1.4	42
13	Incidences and Determinants of Functional Cure During Entecavir or Tenofovir Disoproxil Fumarate for Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 224, 1890-1899.	4.0	40
14	HCC risk post-SVR with DAAs in East Asians: findings from the REAL-C cohort. <i>Hepatology International</i> , 2020, 14, 1023-1033.	4.2	38
15	Comparison of the Abbott RealTime HBV assay with the Roche Cobas AmpliPrep/Cobas TaqMan HBV assay for HBV DNA detection and quantification. <i>Journal of Clinical Virology</i> , 2014, 60, 206-214.	3.1	34
16	Time-Degenerative Factors and the Risk of Hepatocellular Carcinoma after Antiviral Therapy among Hepatitis C Virus Patients: A Model for Prioritization of Treatment. <i>Clinical Cancer Research</i> , 2017, 23, 1690-1697.	7.0	32
17	Scaling up the in-hospital hepatitis C virus care cascade in Taiwan. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 136-143.	8.9	32
18	Association of diabetes and PNPLA3 genetic variants with disease severity of patients with chronic hepatitis C virus infection. <i>Journal of Hepatology</i> , 2015, 62, 512-518.	3.7	30

#	ARTICLE	IF	CITATIONS
19	Genetics Variants and Serum Levels of MHC Class I Chain-related A in Predicting Hepatocellular Carcinoma Development in Chronic Hepatitis C Patients Post Antiviral Treatment. <i>EBioMedicine</i> , 2017, 15, 81-89.	6.1	30
20	Pretreatment glucose status determines HCC development in HCV patients with mild liver disease after curative antiviral therapy. <i>Medicine (United States)</i> , 2016, 95, e4157.	1.0	29
21	Risk stratification of non-alcoholic fatty liver disease across body mass index in a community basis. <i>Journal of the Formosan Medical Association</i> , 2020, 119, 89-96.	1.7	29
22	Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan. <i>Liver International</i> , 2021, 41, 1265-1277.	3.9	29
23	More advanced disease and worse survival in cryptogenic compared to viral hepatocellular carcinoma. <i>Liver International</i> , 2018, 38, 895-902.	3.9	27
24	Serum M2BPGi level and risk of hepatocellular carcinoma after oral anti-viral therapy in patients with chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 1128-1137.	3.7	26
25	The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 567-571.	1.9	25
26	Establishment of an outreach, grouping healthcare system to achieve microelimination of HCV for uremic patients in haemodialysis centres (ERASE-C). <i>Gut</i> , 2021, 70, 2349-2358.	12.1	25
27	First-in-Asian double-blind randomized trial to assess the efficacy and safety of insulin sensitizer in nonalcoholic steatohepatitis patients. <i>Hepatology International</i> , 2021, 15, 1136-1147.	4.2	23
28	The performance of acoustic radiation force impulse imaging in predicting liver fibrosis in chronic liver diseases. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 362-366.	1.9	22
29	Mac-2 Binding Protein Glycosylation Isomer as a Hepatocellular Carcinoma Marker in Patients With Chronic Hepatitis B or C Infection. <i>Hepatology Communications</i> , 2019, 3, 493-503.	4.3	22
30	Pharmacokinetics and pharmacodynamics of pegylated interferon for the treatment of hepatitis B. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2019, 15, 779-785.	3.3	21
31	Cure or curd: Modification of lipid profiles and cardiovascular events after hepatitis C virus eradication. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 920-928.	1.9	20
32	Extrahepatic Malignancy Among Patients With Chronic Hepatitis C After Antiviral Therapy: A Real-World Nationwide Study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>American Journal of Gastroenterology</i> , 2020, 115, 1226-1235.	0.4	19
33	The IL-6/STAT3 pathway upregulates microRNA-125b expression in hepatitis C virus infection. <i>Oncotarget</i> , 2018, 9, 11291-11302.	1.8	19
34	Seroprevalence and clinical characteristics of viral hepatitis in transfusion-dependent thalassemia and hemophilia patients. <i>PLoS ONE</i> , 2017, 12, e0178883.	2.5	18
35	Long-Term Effect of Interferon Plus Ribavirin on Hepatitis B Surface Antigen Seroclearance in Patients Dually Infected with Hepatitis B and C Viruses. <i>PLoS ONE</i> , 2011, 6, e20752.	2.5	18
36	Equal treatment efficacy of direct-acting antivirals in patients with chronic hepatitis C and hepatocellular carcinoma? A prospective cohort study. <i>BMJ Open</i> , 2019, 9, e026703.	1.9	17

#	ARTICLE	IF	CITATIONS
37	Exosome-derived differentiation antagonizing non-protein coding RNA with risk of hepatitis C virus-related hepatocellular carcinoma recurrence. <i>Liver International</i> , 2021, 41, 956-968.	3.9	17
38	Role of hepatitis D virus infection in development of hepatocellular carcinoma among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Scientific Reports</i> , 2021, 11, 8184.	3.3	17
39	New Insights in Recurrent HCV Infection after Liver Transplantation. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-11.	3.3	16
40	Discrepancy between Serological and Virological Analysis of Viral Hepatitis in Hemodialysis Patients. <i>International Journal of Medical Sciences</i> , 2014, 11, 436-441.	2.5	16
41	Peripheral blood mononuclear cells microRNA predicts treatment outcome of hepatitis C virus genotype 1 infection. <i>Antiviral Research</i> , 2014, 105, 135-142.	4.1	16
42	Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients. <i>PLoS ONE</i> , 2015, 10, e0139796.	2.5	16
43	25-Hydroxy vitamin D suppresses hepatitis C virus replication and contributes to rapid virological response of treatment efficacy. <i>Hepatology Research</i> , 2017, 47, 1383-1389.	3.4	16
44	Clinical Efficacy and Post-Treatment Seromarkers Associated with the Risk of Hepatocellular Carcinoma among Chronic Hepatitis C Patients. <i>Scientific Reports</i> , 2017, 7, 3718.	3.3	16
45	Pegylated-Interferon Alpha Therapy for Treatment-Experienced Chronic Hepatitis B Patients. <i>PLoS ONE</i> , 2015, 10, e0122259.	2.5	16
46	Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 518-526.	1.7	15
47	<i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein in the prediction of disease severity in chronic hepatitis B patients. <i>PLoS ONE</i> , 2019, 14, e0220663.	2.5	15
48	Pretreatment Hepatitis B Viral Load Predicts Long-Term Hepatitis B Response After Anti-Hepatitis C Therapy in Hepatitis B/C Dual-Infected Patients. <i>Journal of Infectious Diseases</i> , 2019, 219, 1224-1233.	4.0	15
49	The tertiary prevention of hepatocellular carcinoma in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1768-1774.	2.8	14
50	Post-treatment fibrotic modifications overwhelm pretreatment liver fibrosis in predicting HCC in CHC patients with curative antivirals. <i>Hepatology International</i> , 2018, 12, 544-551.	4.2	14
51	Transition rates to cirrhosis and liver cancer by age, gender, disease and treatment status in Asian chronic hepatitis B patients. <i>Hepatology International</i> , 2021, 15, 71-81.	4.2	14
52	Impact of Sofosbuvir-Based Direct-Acting Antivirals on Renal Function in Chronic Hepatitis C Patients With Impaired Renal Function: A Large Cohort Study From the Nationwide HCV Registry Program (TACR). <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1151-1162.e6.	4.4	14
53	The Impact of Steatosis on Chronic Hepatitis C Progression and Response to Antiviral Treatments. <i>Biomedicines</i> , 2021, 9, 1491.	3.2	14
54	Association of hyperuricemia with disease severity in chronic hepatitis C patients. <i>PLoS ONE</i> , 2018, 13, e0207043.	2.5	13

#	ARTICLE	IF	CITATIONS
55	Early Fibrosis but Late Tumor Stage and Worse Outcomes in Hepatocellular Carcinoma Patients Without Hepatitis B or Hepatitis C. <i>Digestive Diseases and Sciences</i> , 2020, 65, 2120-2129.	2.3	13
56	Sofosbuvir/Velpatasvir for Hepatitis C Virus Infection: Real-World Effectiveness and Safety from a Nationwide Registry in Taiwan. <i>Infectious Diseases and Therapy</i> , 2022, 11, 485-500.	4.0	13
57	Abdominal Splenosis Mimicking Hepatic Tumor: A Case Report. <i>Kaohsiung Journal of Medical Sciences</i> , 2008, 24, 602-607.	1.9	12
58	Hepatitis C viremia interferes with serum hepatitis B virus surface antigen and DNA levels in hepatitis B uremics. <i>Hepatology International</i> , 2014, 8, 224-232.	4.2	12
59	Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin. <i>Medicine (United States)</i> , 2015, 94, e1837.	1.0	12
60	Hepatitis D virus infections among injecting drug users with and without human immunodeficiency virus infection in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 526-530.	1.9	12
61	MicroRNA let-7g cooperates with interferon/ribavirin to repress hepatitis C virus replication. <i>Journal of Molecular Medicine</i> , 2016, 94, 311-320.	3.9	12
62	Elevated serum ferritin level associated with hepatic steatosis and fibrosis in hepatitis C virus-infected patients. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 99-104.	1.4	12
63	Risk of hepatitis C virus related hepatocellular carcinoma between subjects with spontaneous and treatment-induced viral clearance. <i>Oncotarget</i> , 2017, 8, 43925-43933.	1.8	12
64	Neoadjuvant transcatheter arterial chemoembolization does not provide survival benefit compared to curative therapy alone in single hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 77-82.	1.9	11
65	A real-world impact of cost-effectiveness of pegylated interferon/ribavirin regimens on treatment-naïve chronic hepatitis C patients in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 44-49.	1.9	11
66	Cytokeratin-18 and uric acid predicts disease severity in Taiwanese nonalcoholic steatohepatitis patients. <i>PLoS ONE</i> , 2017, 12, e0174394.	2.5	11
67	Updates in the management and treatment of HCV genotype 3, what are the remaining challenges?. <i>Expert Review of Anti-Infective Therapy</i> , 2018, 16, 907-912.	4.4	11
68	Changing epidemiology and viral interplay of hepatitis B, C and D among injecting drug user-dominant prisoners in Taiwan. <i>Scientific Reports</i> , 2021, 11, 8554.	3.3	11
69	Characteristics and Survival Outcomes of Hepatocellular Carcinoma Developed after HCV SVR. <i>Cancers</i> , 2021, 13, 3455.	3.7	11
70	Abbott RealTime HBV Assay Is More Sensitive in Detection of Low Viral Load and Little Impacted by Drug Resistant Mutation in Chronic Hepatitis B Patients under Nucleot(s)ide Analogues Therapy. <i>PLoS ONE</i> , 2014, 9, e101790.	2.5	10
71	The effect of antiviral therapy on serum lipid profiles in chronic hepatitis C. <i>Oncotarget</i> , 2018, 9, 21313-21321.	1.8	10
72	Association of serial serum major histocompatibility complex class I chain-related A measurements with hepatocellular carcinoma in chronic hepatitis C patients after viral eradication. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019, 34, 249-255.	2.8	10

#	ARTICLE	IF	CITATIONS
73	Significant amelioration of hepatitis C virus infection in a hyperendemic area: longitudinal evidence from the COMPACT Study in Taiwan. <i>BMJ Open</i> , 2021, 11, e042861.	1.9	10
74	Outreach onsite treatment with a simplified pangenotypic direct-acting anti-viral regimen for hepatitis C virus micro-elimination in a prison. <i>World Journal of Gastroenterology</i> , 2022, 28, 263-274.	3.3	10
75	PNPLA3 genetic variants determine hepatic steatosis in non-obese chronic hepatitis C patients. <i>Scientific Reports</i> , 2015, 5, 11901.	3.3	9
76	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2 binding protein expression predicts disease severity in chronic hepatitis C patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 394-399.	1.9	9
77	Clusters of Circulating let-7 Family Tumor Suppressors Are Associated with Clinical Characteristics of Chronic Hepatitis C. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4945.	4.1	9
78	Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 186-196.	8.9	9
79	Long-term efficacy of Peginterferon/Ribavirin with and without Lamivudine therapy for HBeAg-positive hepatitis B and C dual infection. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2016, 31, 835-841.	2.8	8
80	The prognostic factors between different viral etiologies among advanced hepatocellular carcinoma patients receiving sorafenib treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 624-632.	1.9	8
81	The prognosis of bulky hepatocellular carcinoma with nonmajor branch portal vein tumor thrombosis. <i>Medicine (United States)</i> , 2019, 98, e15066.	1.0	8
82	Serial serologic changes of hepatitis D virus in chronic hepatitis B patients receiving nucleos(t)ides analogues therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1886-1892.	2.8	8
83	Eradication of hepatitis C virus preserve liver function and prolong survival in advanced hepatocellular carcinoma patients with limited life expectancy. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 145-153.	1.9	8
84	Role of hepatitis D virus in persistent alanine aminotransferase abnormality among chronic hepatitis B patients treated with nucleotide/nucleoside analogues. <i>Journal of the Formosan Medical Association</i> , 2021, 120, 303-310.	1.7	8
85	Potential of novel colchicine dosage schedule for the palliative treatment of advanced hepatocellular carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 616-623.	1.9	8
86	Significant down-regulation of growth hormone receptor expression revealed as a new unfavorable prognostic factor in hepatitis C virus-related hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2021, 27, 313-328.	8.9	8
87	Resubclassification and clinical management for Barcelona Clinic Liver Cancer Stage C hepatocellular carcinoma. <i>Hepatology International</i> , 2021, 15, 946-956.	4.2	8
88	Nationwide registry of glecaprevir plus pibrentasvir in the treatment of HCV in Taiwan. <i>Scientific Reports</i> , 2021, 11, 23473.	3.3	8
89	Elevated on-treatment levels of serum IFN-gamma is associated with treatment failure of peginterferon plus ribavirin therapy for chronic hepatitis C. <i>Scientific Reports</i> , 2016, 6, 22995.	3.3	7
90	Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 473-481.	2.8	7

#	ARTICLE	IF	CITATIONS
91	Dynamics of PBMC gene expression in hepatitis C virus genotype 1-infected patients during combined peginterferon/ribavirin therapy. <i>Oncotarget</i> , 2016, 7, 61325-61335.	1.8	7
92	Longitudinal renal changes in chronic hepatitis B patients treated with entecavir versus TDF: a REAL-B study. <i>Hepatology International</i> , 2022, 16, 48-58.	4.2	7
93	Regorafenib for Taiwanese patients with unresectable hepatocellular carcinoma after sorafenib failure: Impact of alpha-fetoprotein levels. <i>Cancer Medicine</i> , 2022, 11, 104-116.	2.8	7
94	The treatment outcome and impact on blood transfusion demand of Peg-interferon/ribavirin in thalassemic patients with chronic hepatitis C. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 14-23.	1.7	6
95	Interference of hepatitis B virus dual infection in platelet count recovery in chronic hepatitis C patients with curative antiviral therapy. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1108-1114.	2.8	6
96	Lower protein expression levels of MHC class I chain-related gene A in hepatocellular carcinoma are at high risk of recurrence after surgical resection. <i>Scientific Reports</i> , 2018, 8, 15821.	3.3	6
97	Association between cryoglobulinemia and liver fibrosis in chronic hepatitis C patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1897-1903.	2.8	6
98	Disease progression of nonalcoholic steatohepatitis in Taiwanese patients: a longitudinal study of paired liver biopsies. <i>European Journal of Gastroenterology and Hepatology</i> , 2019, 31, 224-229.	1.6	6
99	Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir/asunaprevir. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 151-156.	2.8	6
100	Hepatitis b infection: progress in identifying patients most likely to respond to peginterferon alfa. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 427-435.	3.0	6
101	Genotype distribution, clinical characteristics, and racial differences observed in chronic hepatitis C patients in Pingtung, Taiwan. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 255-260.	1.4	6
102	Anti-HCV antibody titer highly predicts HCV viremia in patients with hepatitis B virus dual-infection. <i>PLoS ONE</i> , 2021, 16, e0254028.	2.5	6
103	Diversity of the association of serum levels and genetic variants of MHC class I polypeptide-related chain A with liver fibrosis in chronic hepatitis C. <i>Oncotarget</i> , 2017, 8, 32618-32625.	1.8	6
104	Body weight changes in treated hepatitis B patients switching to tenofovir alafenamide. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1273-1282.	1.7	6
105	Dynamics of cytokines predicts risk of hepatocellular carcinoma among chronic hepatitis C patients after viral eradication. <i>World Journal of Gastroenterology</i> , 2022, 28, 140-153.	3.3	6
106	The impact of an additional extra-hepatic primary malignancy on the outcomes of patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2017, 12, e0184878.	2.5	5
107	Toll-like 1 genetic variants determine fibrosis regression in chronic hepatitis C patients with curative antivirals. <i>Scientific Reports</i> , 2018, 8, 15058.	3.3	5
108	Integrated care for methadone maintenance patients with hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2019, 35, 501-507.	1.9	5

#	ARTICLE	IF	CITATIONS
109	Elevated interleukin-4 levels predicted advanced fibrosis in chronic hepatitis C. <i>Journal of the Chinese Medical Association</i> , 2019, 82, 277-281.	1.4	5
110	Concordance of SVR12, SVR24 and SVR durability in Taiwanese chronic hepatitis C patients with direct-acting antivirals. <i>PLoS ONE</i> , 2021, 16, e0245479.	2.5	5
111	Evolutionary seroepidemiology of viral hepatitis and the gap in hepatitis C care cascades among uraemic patients receiving haemodialysis in Taiwan—the Formosa-Like Group. <i>Journal of Viral Hepatitis</i> , 2021, 28, 719-727.	2.0	5
112	The association between hepatitis C virus infection and renal function. <i>Journal of the Chinese Medical Association</i> , 2021, 84, 757-765.	1.4	5
113	Post-treatment alpha fetoprotein and platelets predict hepatocellular carcinoma development in dual-infected hepatitis B and C patients after eradication of hepatitis C. <i>Oncotarget</i> , 2018, 9, 12240-12249.	1.8	5
114	The applicability of non-invasive methods for assessing liver fibrosis in hemodialysis patients with chronic hepatitis C. <i>PLoS ONE</i> , 2020, 15, e0242601.	2.5	5
115	Towards a safe hospital: hepatitis C in-hospital micro-elimination program (HCV-HELP study). <i>Hepatology International</i> , 2022, 16, 59-67.	4.2	5
116	Thyroid autoantibodies and dysfunction do not impact the treatment efficacy of peginterferon and ribavirin combination therapy in chronic hepatitis C. <i>Hepatology International</i> , 2012, 6, 613-619.	4.2	4
117	Interferon-associated hepatic steatosis is related to discrepancies in biochemical and virological responses of chronic hepatitis C to IFN-based therapy. <i>Hepatology International</i> , 2013, 7, 162-170.	4.2	4
118	Disease severity and erythropoiesis in chronic hepatitis C. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2017, 32, 864-869.	2.8	4
119	Boceprevir-based triple therapy to rescue HCV genotype 1/HBV dually infected patients refractory to peginterferon plus ribavirin combination therapy in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 497-504.	1.7	4
120	Viral Interference Between Dengue Virus and Hepatitis C Virus Infections. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa272.	0.9	4
121	Progression Rates by Age, Sex, Treatment, and Disease Activity by AASLD and EASL Criteria: Data for Precision Medicine. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 874-885.e4.	4.4	4
122	Long-term outcome of liver complications in patients with chronic HBV/HCV co-infection after antiviral therapy: a real-world nationwide study on Taiwanese Chronic Hepatitis C Cohort (T-COACH). <i>Hepatology International</i> , 2021, 15, 1109-1121.	4.2	4
123	Host and virological characteristics of patients with hepatitis C virus mixed genotype 1 and 2 infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 271-277.	1.9	3
124	Anti-HIV seropositivity was related to HBsAg seropositivity among injecting drug users in Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 96-102.	1.9	3
125	Identification of treatment-experienced hepatitis C patients with poor cost-effectiveness of pegylated interferon plus ribavirin from a real-world cohort. <i>Journal of the Formosan Medical Association</i> , 2018, 117, 54-62.	1.7	3
126	A real world cost effectiveness analysis of interferon-based therapy for HCV naïve super-responders. <i>Journal of the Chinese Medical Association</i> , 2018, 81, 670-675.	1.4	3

#	ARTICLE	IF	CITATIONS
127	Successful Antiviral Therapy Reduces Risk of Schizophrenia Among Chronic Hepatitis C Patients: A Nationwide Real-World Taiwanese Cohort (T-COACH). <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa397.	0.9	3
128	Primary culture of aspiration residual specimens improves the diagnostic accuracy between hepatocellular carcinoma and benign nodules. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 460-466.	1.9	3
129	Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype 2 infection after completed treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2021, 37, 334-345.	1.9	3
130	Long-term risk of end-stage renal diseases with maintenance dialysis among chronic hepatitis C patients after antiviral therapy in Taiwan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2247-2254.	2.8	3
131	An EASL position paper for systemic treatment of hepatocellular carcinoma: Go forward courageously. <i>Journal of Hepatology</i> , 2021, . .	3.7	3
132	The Persistence of Hepatitis C Virus Infection in Hepatocytes Promotes Hepatocellular Carcinoma Progression by Pro-Inflammatory Interleukin-8 Expression. <i>Biomedicines</i> , 2021, 9, 1446.	3.2	3
133	Less liver fibrosis marker increment in overweight chronic hepatitis B patients observed by age-adjusted Fibrosis-4 Index. <i>BMJ Open Gastroenterology</i> , 2020, 7, e000543.	2.7	3
134	Circulating Let-7 Family Members as Non-Invasive Biomarkers for Predicting Hepatocellular Carcinoma Risk after Antiviral Treatment among Chronic Hepatitis C Patients. <i>Cancers</i> , 2022, 14, 2023.	3.7	3
135	The safety and efficacy of peginterferon plus ribavirin in hepatitis C patients concomitant with malignancy other than hepatocellular carcinoma: a multicenter study. <i>Hepatology International</i> , 2013, 7, 180-187.	4.2	2
136	Clinical performance of a new hepatitis B surface antigen quantitative assay with automatic dilution. <i>Kaohsiung Journal of Medical Sciences</i> , 2015, 31, 26-33.	1.9	2
137	Lamivudine switch therapy in chronic hepatitis B patients achieving undetectable hepatitis B virus DNA after 3 years of entecavir therapy: A prospective, open-label, multicenter study. <i>Kaohsiung Journal of Medical Sciences</i> , 2016, 32, 559-566.	1.9	2
138	Hepatocellular carcinoma metastatic to kidney mimicking renal cell carcinoma. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 161-162.	1.9	2
139	Pegylated interferon plus ribavirin combination therapy in postliver transplant recipients with recurrent hepatitis C virus infection. <i>Kaohsiung Journal of Medical Sciences</i> , 2017, 33, 284-289.	1.9	2
140	Primary cultures of aspiration residual specimens predict outcomes of hepatocellular carcinoma patients receiving curative treatment. <i>Kaohsiung Journal of Medical Sciences</i> , 2020, 36, 750-756.	1.9	2
141	Development and Validation of a Risk Score for Liver Cirrhosis Prediction in Untreated and Treated Chronic Hepatitis B. <i>Journal of Infectious Diseases</i> , 2021, 223, 139-146.	4.0	2
142	Comorbidities in patients with chronic hepatitis C and hepatitis B on hemodialysis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2261-2269.	2.8	2
143	Serum <i>Wisteria floribunda</i> agglutinin-positive Mac-2-binding protein expression predicts disease severity in nonalcoholic steatohepatitis patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 261-267.	1.9	2
144	Ledipasvir/sofosbuvir for HCV genotype 1, 2, 4-6 infection: Real-world evidence from a nationwide registry in Taiwan. <i>Journal of the Formosan Medical Association</i> , 2022, 121, 1567-1578.	1.7	2

#	ARTICLE	IF	CITATIONS
145	Factors Associated with Significant Platelet Count Improvement in Thrombocytopenic Chronic Hepatitis C Patients Receiving Direct-Acting Antivirals. <i>Viruses</i> , 2022, 14, 333.	3.3	2
146	Itemization difference of patient-reported outcome in patients with chronic liver disease. <i>PLoS ONE</i> , 2022, 17, e0264348.	2.5	2
147	Low disease awareness as a contributing factor to the high prevalence of hepatitis C infection in Tzukuán, a hyperendemic area of southern Taiwan. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, , .	1.9	2
148	Persistent cryoglobulinemia after antiviral treatment is associated with advanced fibrosis in chronic hepatitis C patients. <i>PLoS ONE</i> , 2022, 17, e0268180.	2.5	2
149	The performance of HCV GT plus RUO reagent in determining Hepatitis C virus genotypes in Taiwan. <i>PLoS ONE</i> , 2021, 16, e0246376.	2.5	1
150	Limited sorafenib anticancer effects on primary cultured hepatocellular carcinoma cells with high <sc><i>NANOG</i></sc> expression. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 157-164.	1.9	1
151	The acceptability of serum sample storage for hepatitis C viral load analysis in chronic hepatitis C patients. <i>Advances in Digestive Medicine</i> , 2019, 6, 58-61.	0.2	0
152	Fulminant Emphysematous Pancreatic Pseudocyst: Infected with Normal Skin Flora. <i>American Journal of Medicine</i> , 2019, 132, e41-e42.	1.5	0
153	Reply to “DAA and HBV/HCV co-infection: Glimmer of light and a few shades of grey”. <i>Journal of Hepatology</i> , 2020, 73, 462.	3.7	0
154	Seroreversion of hepatitis B surface antigen among subjects with resolved hepatitis B virus infection: A community-based cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 3239-3246.	2.8	0
155	The compound annual growth rate of the fibrosis-4 index in chronic hepatitis B patients. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, , .	1.9	0
156	A case of autoimmune hepatitis-Primary biliary cholangitis overlap syndrome without any associated autoantibody. <i>Kaohsiung Journal of Medical Sciences</i> , 2022, 38, 712-713.	1.9	0